GURU.Markets stock price, segment price, and overall market index valuation
The company's share price IO Biotech Inc.
The stock of IO Biotech, an oncology biotech, reflects the potential of its cancer vaccines. The price chart is a classic biotech story, with the value determined by expectations of clinical trial results.
Share prices of companies in the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biopharmaceutical company developing innovative cancer immunotherapies aimed at suppressing immunosuppressive cells. We refer to this technology as "Immuno-oncology." The chart below illustrates the overall dynamics of this cutting-edge field of medicine.
Broad Market Index - GURU.Markets
IO Biotech is a Danish biopharmaceutical company developing cancer immunotherapy aimed at suppressing immune-suppressive cells. Its shares (ADR) are a component of the GURU.Markets index. The chart below shows how its performance compares to the US market.
Change in the price of a company, segment, and market as a whole per day
IOBT - Daily change in the company's share price IO Biotech Inc.
For IO Biotech, Inc., an immuno-oncology company, daily price change is a measure of extreme volatility. It reflects the market's reaction to clinical trial data and is a critical parameter for risk assessment formulas on the System.GURU.Markets platform.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
IO Biotech, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with IOBT's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
IO Biotech is an immuno-oncology company developing therapies to fight cancer by activating the immune system. Its shares follow the rhythm of clinical trials. This scientifically based volatility is an important part of the diverse and complex picture of stock market movements.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization IO Biotech Inc.
IO Biotech, Inc.'s year-to-date performance is a story of next-generation immuno-oncology vaccine development. Its 12-month market cap is entirely dependent on Phase III clinical trial data. The success of its approach, which targets immunosuppressive cells, could lead to a breakthrough in the treatment of cancers such as melanoma.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
IO Biotech, Inc. is a clinical-stage biotech company developing immunotherapy for cancer treatment. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs typical of the biotech sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
IO Biotech is a clinical-stage biotech company whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart lives in a world of its own.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization IO Biotech Inc.
IO Biotech is an immuno-oncology company developing cancer vaccines. Its monthly performance is entirely tied to the results of its clinical trials. Any news, positive or negative, about its flagship programs triggers an immediate and strong investor reaction, which is typical for biotech.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biotech company developing immunotherapy for cancer treatment. Its approach aims to simultaneously activate and direct T cells to fight tumors. The graph below shows the overall dynamics of the biotech sector, where the search for new immuno-oncology methods remains a top priority.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
IO Biotech is a clinical-stage biotech company developing cancer immunotherapy. Its shares, like all companies in this sector, are preoccupied with anticipation of research results. Positive data can trigger explosive growth, while failures can lead to a collapse, and these events are in no way related to the overall state of the stock market.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization IO Biotech Inc.
Shares of IO Biotech, an immuno-oncology company, reflect the company's search for new ways to fight cancer every week. Their price movements reflect data from clinical trials of their vaccines, which are designed to mobilize the immune system against tumors resistant to other therapies.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
IO Biotech is a Danish biotech company developing immunotherapy for cancer treatment. Like its peers in the sector, successful clinical trials are key drivers of its stock price growth. Use this chart to understand whether IO Biotech's weekly performance reflects its own scientific data or a general wave of optimism in the sector.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
IO Biotech is a biotech company. Its shares can be highly volatile and sensitive to research news. This chart will help you understand whether IO Biotech is living in its own world of clinical trials, or whether the overall market environment and risk appetite in biotech are influencing its stock price.
Market capitalization of the company, segment and market as a whole
IOBT - Market capitalization of the company IO Biotech Inc.
The IO Biotech market capitalization chart tells the story of a Danish biotech company developing an immunotherapy for cancer treatment aimed at suppressing immunosuppressive cells in tumors. Its volatile performance reflects investors' assessment of the potential of its unique approach and clinical trial data.
IOBT - Share of the company's market capitalization IO Biotech Inc. within the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biotech developing a novel cancer immunotherapy that targets both tumor cells and the immune-suppressing tumor microenvironment. Its market cap reflects the potential of this dual approach. The chart below shows how the market views its chances in this competitive field.
Market capitalization of the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biotech company developing immunotherapy for cancer treatment. The chart below shows the overall market capitalization of the oncology sector. Its dynamics provide the backdrop against which IO Biotech is attempting to prove the effectiveness of its approach targeting immunosuppressive cells.
Market capitalization of all companies included in a broad market index - GURU.Markets
IO Biotech is a clinical-stage biotech developing immunotherapies for cancer. Its market cap reflects the hope that its approach, which targets immunosuppressive cells, will prove effective. Its volatility reflects the high stakes of the oncology world.
Book value capitalization of the company, segment and market as a whole
IOBT - Book value capitalization of the company IO Biotech Inc.
IO Biotech's balance sheet represents its capital invested in clinical trials of innovative cancer immunotherapy aimed at suppressing immunosuppressive cells. This is the tangible, scientific foundation for a new approach in oncology. How has this biotech asset changed during development? The chart below shows its dynamics.
IOBT - Share of the company's book capitalization IO Biotech Inc. within the market segment - Oncology immuno-therapy
IO Biotech develops immunotherapy for cancer treatment, which requires modern R&D laboratories. The chart shows the share of these knowledge-intensive tangible assets in the pharmaceutical sector, reflecting the physical foundation of its fight against cancer.
Market segment balance sheet capitalization - Oncology immuno-therapy
IO Biotech is a biotech company focused on immuno-oncology. Its main assets are patents and R&D. The book value chart shows how "light" its capital base is, which is typical for R&D companies.
Book value of all companies included in the broad market index - GURU.Markets
IO Biotech is a pioneer in cancer immunotherapy aimed at suppressing immunosuppressive cells. Its book value represents its laboratories and the capital needed to conduct large-scale clinical trials. The chart shows the material foundation on which this new approach to oncology treatment is built.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - IO Biotech Inc.
IO Biotech's balance sheet is capital. But the market sees it as the creator of a new approach to immunotherapy. The chart shows the "hope factor": the premium investors are paying for the potential of its vaccines to change the standard of cancer treatment.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
IO Biotech is a biotech company developing immunotherapy for cancer treatment. Its approach is aimed at mobilizing the immune system against tumors. The chart shows the high expectations investors have for its unique therapeutic platform.
Market to book capitalization ratio for the market as a whole
IO Biotech is a biotech company developing immunotherapy that targets immunosuppressive cells within tumors. Its approach is to "turn off" cancer's defenses. This chart shows the overall market valuation, but how do investors value a company that is exploring new ways to make tumors vulnerable to the immune system?
Debts of the company, segment and market as a whole
IOBT - Company debts IO Biotech Inc.
IO Biotech, a clinical-stage immuno-oncology company, is developing innovative cancer vaccines. This chart shows how it is raising capital to fund its expensive clinical trials. It's a financial bet on a new approach to mobilizing a patient's own immune system to fight tumors.
Market segment debts - Oncology immuno-therapy
IO Biotech is a clinical-stage immuno-oncology company developing vaccines for cancer treatment. Activating a patient's own immune system is a promising approach. This chart shows how the company is raising capital to fund its expensive and lengthy clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio IO Biotech Inc.
IO Biotech is a clinical-stage biopharmaceutical company developing cancer immunotherapy. This chart is a critical indicator of its financial health. It shows how much the company relies on debt to fund its expensive and lengthy clinical trials, which is typical for high-risk biotech companies.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
IO Biotech is a biotech company developing T-cell-based immunotherapies for cancer treatment. This chart shows the overall debt burden in the immuno-oncology sector. It helps understand how the industry finances its extensive and expensive clinical programs and how IO Biotech manages its capital in this competitive environment.
Debt to book value of all companies in the market
IO Biotech is a clinical-stage biopharmaceutical company specializing in immuno-oncology. Like most biotechs without a commercial product, it relies on equity capital. The market's overall debt burden chart doesn't reflect its reality, which is burning through investors' money for the sake of a potential scientific breakthrough.
P/E of the company, segment and market as a whole
P/E - IO Biotech Inc.
This metric for IO Biotech, an immuno-oncology company, illustrates investor expectations. Its value is based not on profits, but on the potential of its vaccines aimed at suppressing immunosuppressive cells in tumors. It's an estimate of a future breakthrough in cancer treatment, associated with the high risk of clinical trials.
P/E of the market segment - Oncology immuno-therapy
Immuno-oncology, where IO Biotech develops therapeutic vaccines, is a promising field. This chart shows the average valuation for biopharmaceutical companies. It helps to understand that IO Biotech is valued as a scientific platform, whose value depends entirely on the success of its vaccines in clinical trials for cancer treatment.
P/E of the market as a whole
IO Biotech, Inc. is a clinical-stage biotech company developing cancer immunotherapy that targets immunosuppressive cells in tumors. This approach is novel. This chart, reflecting investor risk appetite, demonstrates the market's willingness to invest in innovative, yet unproven, oncology platforms like IO Biotech's.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company IO Biotech Inc.
IO Biotech is a clinical-stage biotech developing T-cell-based immunotherapy for cancer. This chart reflects investor speculative expectations for its approach to treating solid tumors. The trend represents the market's assessment of the potential of its clinical programs.
%20P%2FE%20IO%20Biotech%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-IO-Biotech-Inc.&v=1772513411666 "Chart of the company's future (projected) P/E IO Biotech Inc.")
Future (projected) P/E of the market segment - Oncology immuno-therapy
IO Biotech is a biotech company developing cancer immunotherapy aimed at suppressing immunosuppressive cells in tumors. This chart shows profitability expectations for the oncology sector. It helps understand how the market views this unique treatment approach and the potential of its leading candidates.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772513411672 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
IO Biotech, Inc. is a clinical-stage biopharmaceutical company developing cancer immunotherapy aimed at suppressing immunosuppressive cells in tumors. This chart shows investors' risk appetite. For a company with an innovative approach to oncology, it reflects the market's willingness to fund new strategies in the fight against cancer.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513411675 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit IO Biotech Inc.
IO Biotech, Inc. is a clinical-stage biotechnology company developing cancer immunotherapy targeting immunosuppressive cells. The financial outcome illustrated in this chart is comprised of clinical trial costs. It reflects the cost of developing a new approach in immuno-oncology.
Profit of companies in the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biotech company developing immunotherapeutics for the treatment of cancer. Its approach focuses on activating T cells to combat immunosuppressive cells within tumors. This graph illustrates how new approaches in immuno-oncology can overcome existing limitations and create enormous profit potential.
Overall market profit
IO Biotech is a clinical-stage biotech company developing immunotherapy for cancer treatment. Its approach is based on mobilizing the immune system against cells that suppress the immune response. Like many of its peers, the overall economic situation, reflected in this chart, determines the availability of capital to fund expensive research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company IO Biotech Inc.
IO Biotech is a clinical-stage biopharmaceutical company developing immunotherapy for cancer treatment. The earnings (loss) forecast shown in the chart represents analysts' bet on the success of its unique approach to activating the immune system against tumors.
%20profit%20of%20the%20company%20IO%20Biotech%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-IO-Biotech-Inc.&v=1772513411732 "Graph of future (projected) profit of the company IO Biotech Inc.")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biopharmaceutical company developing immunotherapeutics that target immunosuppressive cells in the tumor microenvironment. This chart shows the revenue forecast for the immuno-oncology sector, allowing one to assess how IO Biotech's innovative approach can complement existing cancer treatments.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772513411764 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
IO Biotech is a biotech company developing immunotherapy for cancer treatment. Its future depends on the success of clinical trials. This graph, reflecting investor risk appetite, impacts the availability of capital for funding long-term and risky projects in the biotech sector.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513411796 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - IO Biotech Inc.
IO Biotech is a biotech company developing cancer immunotherapy targeting immunosuppressive cells. This chart reflects investor expectations for its innovative approach. The valuation is a bet on the success of its clinical trials in the complex field of oncology.
P/S market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biopharmaceutical company developing cancer immunotherapy aimed at suppressing immunosuppressive cells in tumors. This chart shows the industry average price-to-sales ratio, reflecting investor expectations for the company's innovative approach to fighting cancer.
P/S of the market as a whole
IO Biotech is a clinical-stage biopharmaceutical company developing immunotherapy for cancer treatment based on a unique approach targeting immunosuppressive cells. This chart helps understand how the market evaluates innovative but risky approaches in the competitive field of immuno-oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company IO Biotech Inc.
IO Biotech is a clinical-stage biotech developing immunotherapy for cancer. This chart shows its valuation relative to projected future sales. It reflects investor expectations for the success of its approach, which targets immunosuppressive cells in tumors.
%20P%2FS%20IO%20Biotech%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-IO-Biotech-Inc.&v=1772513411846 "The graph of the company's future (projected) P/S IO Biotech Inc.")
Future (projected) P/S of the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biotech company developing cancer immunotherapy that targets immunosuppressive cells in the tumor microenvironment. This chart reflects investor expectations for its innovative approach and potential future revenue from its oncology drugs.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772513411852 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
IO Biotech is a clinical-stage biotech developing immunotherapy for cancer treatment. Its value is determined by the potential of its scientific developments. This chart of general expectations for IOBT is a baseline. The company's success depends on the results of clinical trials, not the overall economic climate, and could create its own strong trend.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513411868 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales IO Biotech Inc.
This chart illustrates the financial trajectory of a biotech company. For IO Biotech, which develops immuno-oncology vaccines, it reflects funds received from investors to finance clinical trials, not commercial revenue from sales of its drug candidates.
Sales of companies in the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biotech company developing cancer immunotherapy targeting immunosuppressive cells. This chart shows revenue in the oncology segment. The success of IO Biotech's approach could offer a powerful new tool for fighting cancer and become a significant growth driver for the entire sector.
Overall market sales
IO Biotech is a biotechnology company developing immuno-oncology vaccines for the treatment of cancer. Its approach is aimed at activating the immune system against tumor cells. The company is at the forefront of medical science, and its successes could lead to the creation of new treatment standards, advancing the entire healthcare sector.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company IO Biotech Inc.
IO Biotech is a biotech company developing cancer immunotherapy aimed at suppressing immunosuppressive cells in the tumor microenvironment. Future sales projections depend on the success of its clinical trials.
%20sales%20of%20the%20company%20IO%20Biotech%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-IO-Biotech-Inc.&v=1772513411902 "Schedule of future (projected) sales of the company IO Biotech Inc.")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
IO Biotech, Inc. is a biotech company developing immuno-oncology drugs targeting immunosuppressive cells. The outlook for this cutting-edge sector shows enormous potential. The graph reflects expectations for therapies that can "unlock" the immune response and make other treatments more effective.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772513411904 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
IO Biotech is a biotech company developing immunotherapy for cancer treatment. Its prospects depend entirely on the success of clinical trials. The overall economic situation, reflected in this chart, does not affect the need for treatment but is important for assessing the investment attractiveness and capital availability of biotech companies.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513411911 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality IO Biotech Inc.
IO Biotech is a biotech company developing immuno-oncology therapies for cancer treatment. Being in late-stage clinical trials, it incurs significant R&D expenses. This chart illustrates its current financial model: intensive investment in research to bring the next generation of cancer vaccines to market.
Market segment marginality - Oncology immuno-therapy
IO Biotech is a clinical-stage biotechnology company developing cancer immunotherapy targeting immunosuppressive cells. Its profitability depends on the success of its unique approach. This metric reflects the structure of its research investments compared to other immuno-oncology companies.
Market marginality as a whole
IO Biotech, Inc. is a clinical-stage biotech company developing immunotherapy for cancer. This chart shows the company's gross profit margin. Compared to this, IO Biotech is a classic pharmaceutical venture capital story. The company is unprofitable, and its market capitalization is based on investors' hopes for the success of its clinical trials.
Employees in the company, segment and market as a whole
Number of employees in the company IO Biotech Inc.
IO Biotech is a clinical-stage biotech company developing immunotherapies for cancer treatment. Its team of scientists and clinicians is working to advance its vaccines. Growth on this chart would indicate the expansion of its clinical programs, particularly moving into late-stage trials, which requires a significant increase in staff.
Share of the company's employees IO Biotech Inc. within the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biotech company developing a novel immuno-oncology therapy aimed at suppressing immunosuppressive cells in tumors. This chart highlights its scientific leadership, reflecting the percentage of leading immunologists working on this innovative approach to cancer treatment that IO Biotech is attracting.
Number of employees in the market segment - Oncology immuno-therapy
IO Biotech is a clinical-stage biopharmaceutical company developing immunotherapy for cancer treatment. This chart shows the dynamics of one of the most competitive and capital-intensive sectors. The growth of the scientific team here is directly linked to progress in clinical trials, which are a crucial step toward drug approval.
Number of employees in the market as a whole
IO Biotech, Inc. is a Danish biotech company developing cancer immunotherapy. Their world is laboratories and clinics. The overall economic situation, illustrated by this chart, is of no direct importance to them. The success or failure of their clinical trials is the only factor that determines their future and ability to raise capital.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company IO Biotech Inc. (IOBT)
IO Biotech is a Danish biotech company developing cancer immunotherapy aimed at suppressing immunosuppressive cells in tumors. This chart demonstrates how the market values breakthrough scientific approaches. The high market capitalization per employee reflects the enormous potential of their unique platform for developing a new class of anti-cancer drugs.
%20of%20the%20company%20IO%20Biotech%20Inc.%20(IOBT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-IO-Biotech-Inc.-IOBT&v=1772513411951 "Chart of market capitalization per employee (in thousands of dollars) of the company IO Biotech Inc. (IOBT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
IO Biotech is an immuno-oncology company developing cancer vaccines. As with other biotech companies, its market capitalization is an advance payment on future success. This chart vividly illustrates this: investors are willing to pay huge sums for the scientific team's potential, which is reflected in the extremely high market valuation per employee.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772513411952 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
IO Biotech is a clinical-stage biopharmaceutical company developing immunotherapy for cancer. This chart reflects the high valuation per employee typical for biotech companies, where the company's value is based entirely on the potential of its lead drug candidates.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513411954 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company IO Biotech Inc. (IOBT)
IO Biotech is a biotech company developing immuno-oncology drugs aimed at suppressing immunosuppressive cells in tumors. This is R&D. This negative metric reflects the company's capital burn rate. It shows how much the company spends on each scientist and physician to conduct clinical trials of its new therapeutic platform.
%20Chart%20IO%20Biotech%20Inc.%20(IOBT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-IO-Biotech-Inc.-IOBT&v=1772513411956 "Company Profit Per Employee (in thousands of dollars) Chart IO Biotech Inc. (IOBT)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
IO Biotech (IOBT) is a biotech company developing immuno-oncology cancer treatments. Like other R&D companies in this field, this chart represents a future target, not a current reality. Currently, profitability is negative. Success for IOBT would mean that their research team has created a product that will transform medicine and deliver enormous returns.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772513411961 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
IO Biotech (IOBT) is a biotech company working in the field of immuno-oncology. Currently in the clinical stage, the company is focused on R&D. Negative earnings per employee demonstrates to investors the "cost" of maintaining a team of scientists developing a new generation of cancer drugs before commercial revenue has been generated.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513411969 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee IO Biotech Inc. (IOBT)
IO Biotech is a clinical-stage biotech developing cancer immunotherapy. This chart reflects its focus on research. Lack of revenue is the norm. This metric demonstrates enormous potential: if successful, revenue per scientist could be astronomical.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-IO-Biotech-Inc.-IOBT&v=1772513411975 "Sales chart per company employee IO Biotech Inc. (IOBT)")
Sales per employee in the market segment - Oncology immuno-therapy
IO Biotech is a biotech company developing immuno-oncology drugs targeting immune checkpoint inhibitors. During the R&D phase, this metric reflects how effectively their research team generates revenue (e.g., from partnerships) per employee, which is critical for funding their development.
Sales per employee for the market as a whole
IO Biotech is a clinical-stage biotech company developing cancer immunotherapy aimed at suppressing tumor immunosuppressive mechanisms. It's an R&D business. This chart shows revenue per employee, which, as expected, is zero. It emphasizes that the company doesn't sell products but invests in clinical trials.
Short shares by company, segment and market as a whole
Shares shorted by company IO Biotech Inc. (IOBT)
IO Biotech is a biotech company developing immuno-oncology drugs aimed at suppressing immunosuppressive cells in tumors. This chart shows bearish bets. These bears are betting that clinical trials will not prove the effectiveness of this approach or that it will have no advantage over existing checkpoint inhibitors.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-IO-Biotech-Inc.-IOBT&v=1772513411979 "Short Shares Chart for the Company IO Biotech Inc. (IOBT)")
Shares shorted by market segment - Oncology immuno-therapy
IO Biotech is a biotech company developing T-cell-based immunotherapy for cancer treatment. This chart shows overall short positions in the biotech sector. A high chart reflects general market skepticism about the sector, possibly due to fears of research failures or tightening regulatory policies (e.g., the FDA).
Shares shorted by the overall market
IO Biotech (IOBT) is a clinical-stage biotech company working in immuno-oncology. Its survival depends on access to funding. When this market pessimism indicator rises, the window for raising capital slams shut. Investors panic and flee unprofitable biotechs.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator IO Biotech Inc. (IOBT)
IO Biotech is a clinical-stage biotech. Its shares are extremely sensitive to trial news. This chart can surge above 70 on positive R&D data. Oversold territory (<30) often reflects research setbacks, funding concerns, or general risk aversion.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-IO-Biotech-Inc.-IOBT&v=1772513411986 "RSI 14 indicator chart for the company's stock IO Biotech Inc. (IOBT)")
RSI 14 Market Segment - Oncology immuno-therapy
IO Biotech (IOBT) is a biotech company, a cancer hunter (immuno-oncology). The oncology (biotech) sector thrives on news. RSI_14_Seg shows the "temperature" of this entire segment. It's vital to understand: is IOBT's growth due to its R&D or is the entire biotech sector simply overheated by expectations?
RSI 14 for the overall market
For IO Biotech, a biotech company in the R&D stage, this chart is a lifeline showing capital availability. During moments of market euphoria, investors are willing to "buy the dream" and fund breakthrough but risky research. When the market panics, the money supply is turned off, and cash-burning companies face a liquidity crisis.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast IOBT (IO Biotech Inc.)
IO Biotech is a clinical-stage biotech developing cancer immunotherapy (based on IDO) aimed at suppressing tumor defenses. This chart shows the average target price. Analysts' estimates are based on clinical data for their lead candidates and their potential for treating solid tumors.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-IOBT-IO-Biotech-Inc.&v=1772513411995 "A chart showing analyst consensus forecasts for the expected stock price. IOBT (IO Biotech Inc.)")
The difference between the consensus estimate and the actual stock price IOBT (IO Biotech Inc.)
IO Biotech is a Danish immuno-oncology company developing a novel approach to cancer treatment by targeting regulatory T cells (Tregs). This chart illustrates the analyst community's opinion on the company's future. It measures the distance between the stock price and the target, reflecting their belief in this complex yet promising scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-IOBT-IO-Biotech-Inc.&v=1772513412003 "A chart showing the difference between the consensus forecast and the actual stock price. IOBT (IO Biotech Inc.)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
IO Biotech is a biotech company developing immunotherapy (based on T-win) for the treatment of "cold" tumors (cancers that "hide" from the immune system). This chart reflects analyst expectations for the entire immunotherapy sector. It shows how confident experts are in the success of this R&D platform.
Analysts' consensus forecast for the overall market share price
IO Biotech (IOBT) is a clinical-stage biopharmaceutical company developing "immune vaccines" for cancer. Their goal is to train the patient's immune system to recognize and attack tumors. This chart shows the overall risk appetite, reflecting the willingness of investors to fund breakthrough but high-risk R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index IO Biotech Inc.
IO Biotech is a clinical-stage biotech focused on immuno-oncology. Their signature product is T-win vaccines, which target cancer's insidious mechanisms (IDOs) to awaken the immune system. This chart is a clear indicator of faith in their R&D. Its dynamics depend entirely on their (very risky) clinical trial data, particularly in melanoma.
AKIMA Market Segment Index - Oncology immuno-therapy
IO Biotech is a Danish biotech company developing immunotherapy (IO-102/IO-103) to combat cancer by activating T cells against specific targets. This chart shows the average index for the immunotherapy sector. It helps investors assess how IO Biotech's scientific approach compares to the industry average.
The AKIM Index for the overall market
IO Biotech is a biotech company developing cancer vaccines that modulate the tumor immune microenvironment (T-win platform). This chart, which reflects the market average, is an indicator of risk appetite. It shows the macro backdrop critical for funding this cutting-edge immuno-oncology platform.
